Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTPN2 inhibitor
- Development stage
- Preclinical
- Lead developer
- Eilean Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PTPN2 inhibitor is a small molecule drug candidate being developed by Eilean Therapeutics for the treatment of solid tumors. It functions by inhibiting Protein Tyrosine Phosphatase Non-Receptor Type 2 (PTPN2), a key negative regulator of the JAK/STAT signaling pathway and T-cell receptor signaling. By blocking PTPN2, the drug aims to enhance the activation and proliferation of tumor-infiltrating lymphocytes (TILs) and increase the sensitivity of tumor cells to interferon-gamma-mediated cell death. This mechanism is intended to overcome immune evasion in the tumor microenvironment, potentially serving as a potent immuno-oncology (IO) therapy either as a monotherapy or in combination with existing checkpoint inhibitors.
- Other names
- PTPN2 inhibitor (Eilean Therapeutics)PTPN2 inhibitor-Eilean Therapeutics Australia-PTPN2-small molecule inhibitor-IO-Solid TumorsPTPN-2 inhibitor-Eilean Therapeutics Australia-PTPN2-small molecule inhibitor-IO-Solid TumorsPTPN 2 inhibitor-Eilean Therapeutics Australia-PTPN2-small molecule inhibitor-IO-Solid Tumors
02
Targets
PTPN1 (Protein tyrosine phosphatase 1B)PTPN2
Beyond the preview
Go deeper on PTPN2 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTPN2 inhibitor.